🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Daphne Stewart

University of Southern California

ORCID: 0000-0001-9845-8375
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile
0.114Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

BRCA germline mutations in multiethnic gynecologic patients: A 10-year retrospective analysis from a single cancer institute

PLoS ONE(2023)10.1371/journal.pone.0286998
Top 72%
0.114DataRank
Top 72%1 citations

Susan Shehayeb, Nicole Lugo Santiago, Laura Kruper, Ernest Han, Edward Wang +5 more

Papers

Driven by 14 papers — median percentile 28. Top paper: “Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer”.

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

The Oncologist(2023)10.1093/oncolo/oyad026
N/A
0.580DataRank · unranked
14 citations

Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang +10 more

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

Cancers(2022)10.3390/cancers14174279
N/A
0.385DataRank · unranked
12 citations

Susan E. Yost, Jin Sun Lee, Paul Frankel, Christopher Ruel, Yujie Cui +13 more

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study

Therapeutic Advances in Medical Oncology(2023)10.1177/17588359231210675
N/A
0.296DataRank · unranked
5 citations

Colt A. Egelston, Oscar Colunga Flores, Shyambabu Chaurasiya, David Pei‐Cheng Lin, Helen Chang +17 more

BRCA germline mutations in multiethnic gynecologic patients: A 10-year retrospective analysis from a single cancer institute

PLoS ONE(2023)10.1371/journal.pone.0286998
Top 72%
0.114DataRank
Top 72%1 citations

Susan Shehayeb, Nicole Lugo Santiago, Laura Kruper, Ernest Han, Edward Wang +5 more

Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer

Journal of Clinical Medicine(2023)10.3390/jcm12051906
N/A
0DataRank · unranked
4 citations

Sayeh Lavasani, Leon Cristobal, Niki Tank Patel, Mina S. Sedrak, Daphne Stewart +10 more

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

Breast Cancer(2023)10.1007/s12282-023-01473-2
N/A
0DataRank · unranked
7 citations

Carolyn E. Behrendt, Saro Kasparian, Tina Nguyen, Mina S. Sedrak, Sayeh Lavasani +7 more

Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0394
N/A
0DataRank · unranked
4 citations

Paul Frankel, Mihaela Cristea, Melissa Eng, Raechelle Tinsley, Shannon Dempsey +5 more

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan

Cancer Medicine(2024)10.1002/cam4.70096
N/A
0DataRank · unranked
14 citations

Veronica Jones, Wai Yu, Linda D. Bosserman, Sayeh Lavasani, Niki Patel +6 more

Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients with Ovarian Cancer with Peritoneal Metastases: A Multicenter US Phase I Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-18432-0
N/A
0DataRank · unranked
4 citations

Rosemary Senguttuvan, Nora Ruel, Paul Frankel, Susan E. Yost, Sarah Cole +16 more

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer

The Oncologist(2020)10.1002/onco.13574
N/A
0DataRank · unranked
43 citations

Jin Sun Lee, Susan E. Yost, Sierra Min Li, Paul Frankel, Christopher Ruel +17 more

MammaTrace – a cell-free DNA methylation plasma only assay for minimal residual disease detection in breast cancer patients

medRxiv(2025)10.1101/2025.05.20.25328012
N/A
0DataRank · unranked
0 citations

Alex J. Kalfa, Gerald Gooden, Juan Pablo Lewinger, Marissa Pacheco, Jessica Gayton +10 more

Strategies to Improve Participation of Older Adults in Cancer Research

Journal of Clinical Medicine(2020)10.3390/jcm9051571
N/A
0DataRank · unranked
30 citations

Eutiquio Gutierrez, Abhay Tiwari, Simran Padam, Daneng Li, William Dale +15 more

Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.1060
N/A
0DataRank · unranked
2 citations

Carolyn E. Behrendt, Susan E. Yost, Niki Patel, Raynald Samoa, Daphne Stewart +6 more

Cisplatin-induced nephrotoxicity in hyperthermic intraperitoneal chemotherapy (HIPEC) is mitigated by sodium thiosulfate: Clinical and toxicotranscriptomic results of a prospective trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5570
N/A
0DataRank · unranked
1 citations

Ernest Han, Mustafa Raoof, Xiwei Wu, Hyejin Cho, Stephen Lee +11 more